David N. Assis, MD

• Allen Bale
• Amr Sayed
• Anahita Rabiee
• Ariel Jaffe
• Badr Al Bawardy
• Cary Caldwell
• Deborah Proctor
• Dhanpat Jain
• James Boyer
• Jill Gaidos
• Julius Chapiro
• Lin Leng
• Maor Sauler
• Maria Ciarleglio
• Pramod Mistry
• Richard Bucala
• Sanjay Kulkarni
• Silvia Vilarinho
• Swathi Krishnan
• Wajih Kidwai
• Xuchen Zhang

Autoimmune Diseases; Cystic Fibrosis; Hepatitis; Liver; Liver Diseases

Hepatitis

• Reply.Bowlus C, Arrivé L, Bergquist A, Deneau M, Forman L, Ilyas S, Lunsford K, Martinez M, Sapisochin G, Shroff R, Tabibian J, Assis D. Reply. Hepatology 2023, Publish Ahead of Print PMID: 36695291, DOI: 10.1097/hep.0000000000000305.
• Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel diseaseSayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.
• Reply: Living donor liver transplantation for people with PSC.Forman L, Sapisochin G, Assis D, Arrivé L, Bergquist A, Bowlus C, Deneau M, Ilyas S, Lunsford K, Martinez M, Shroff R, Tabibian J. Reply: Living donor liver transplantation for people with PSC. Hepatology 2023, Publish Ahead of Print PMID: 36732294, DOI: 10.1097/hep.0000000000000210.
• AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinomaBowlus CL, Arrivé L, Bergquist A, Deneau M, Forman L, Ilyas SI, Lunsford KE, Martinez M, Sapisochin G, Shroff R, Tabibian JH, Assis DN. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma Hepatology 2022, 77: 659-702. PMID: 36083140, DOI: 10.1002/hep.32771.
• Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary CholangitisGallucci GM, Alsuwayt B, Auclair AM, Boyer JL, Assis DN, Ghonem NS. Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis Inflammation 2022, 45: 2570-2581. PMID: 35838934, DOI: 10.1007/s10753-022-01713-1.
• Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitisHarrington C, Krishnan S, Mack CL, Cravedi P, Assis DN, Levitsky J. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis Hepatology 2022, 76: 1862-1879. PMID: 35611859, PMCID: PMC9796683, DOI: 10.1002/hep.32591.
• Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis.Efe C, Lammert C, Taşçılar K, Dhanasekaran R, Ebik B, Higuera-de la Tijera F, Calışkan AR, Peralta M, Gerussi A, Massoumi H, Catana AM, Purnak T, Rigamonti C, Aldana AJG, Khakoo N, Nazal L, Frager S, Demir N, Irak K, Melekoğlu-Ellik Z, Kacmaz H, Balaban Y, Atay K, Eren F, Alvares-da-Silva MR, Cristoferi L, Urzua Á, Eşkazan T, Magro B, Snijders R, Barutçu S, Lytvyak E, Zazueta GM, Demirezer-Bolat A, Aydın M, Heurgue-Berlot A, De Martin E, Ekin N, Yıldırım S, Yavuz A, Bıyık M, Narro GC, Kıyıcı M, Akyıldız M, Kahramanoğlu-Aksoy E, Vincent M, Carr RM, Günşar F, Reyes EC, Harputluoğlu M, Aloman C, Gatselis NK, Üstündağ Y, Brahm J, Vargas NCE, Güzelbulut F, Garcia SR, Aguirre J, Anders M, Ratusnu N, Hatemi I, Mendizabal M, Floreani A, Fagiuoli S, Silva M, Idilman R, Satapathy SK, Silveira M, Drenth JPH, Dalekos GN, Assis DN, Björnsson E, Boyer JL, Yoshida EM, Invernizzi P, Levy C, Montano-Loza AJ, Schiano TD, Ridruejo E, Wahlin S. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. Liver International : Official Journal Of The International Association For The Study Of The Liver 2022, 42: 607-614. PMID: 34846800, DOI: 10.1111/liv.15121.
• Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitisAlrabadi LS, Dutton A, Rabiee A, Roberts SJ, Deng Y, Cusack L, Silveira MG, Ciarleglio M, Bucala R, Sinha R, Boyer JL, Assis DN. Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis JHEP Reports 2022, 4: 100450. PMID: 35434588, PMCID: PMC9011026, DOI: 10.1016/j.jhepr.2022.100450.
• PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBDSayed A, Silveira M, Assis D, Deng Y, Gaidos J, Proctor D, Al-Bawardy B. PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBD Gastroenterology 2022, 162: s76. DOI: 10.1053/j.gastro.2021.12.161.
• PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBDSayed A, Silveira M, Assis D, Deng Y, Gaidos J, Proctor D, Al-Bawardy B. PREDICTORS AND OUTCOMES OF BIOLOGIC/IMMUNOSUPPRESSIVE THERAPY FOR PSC-ASSOCIATED IBD Inflammatory Bowel Diseases 2022, 28: s76-s76. DOI: 10.1093/ibd/izac015.124.
• Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study.Efe C, Dhanasekaran R, Lammert C, Ebik B, Higuera-de la Tijera F, Aloman C, Rıza Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM, Torgutalp M, Purnak T, Rigamonti C, Gomez Aldana AJ, Khakoo N, Kacmaz H, Nazal L, Frager S, Demir N, Irak K, Ellik ZM, Balaban Y, Atay K, Eren F, Cristoferi L, Batıbay E, Urzua Á, Snijders R, Kıyıcı M, Akyıldız M, Ekin N, Carr RM, Harputluoğlu M, Hatemi I, Mendizabal M, Silva M, Idilman R, Silveira M, Drenth JPH, Assis DN, Björnsson E, Boyer JL, Invernizzi P, Levy C, Schiano TD, Ridruejo E, Wahlin S. Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology (Baltimore, Md.) 2021, 73: 2099-2109. PMID: 33713486, PMCID: PMC8250536, DOI: 10.1002/hep.31797.
• Role of Biliary Organoids in Cholestasis Research and Regenerative MedicineSoroka CJ, Roberts SJ, Boyer JL, Assis DN. Role of Biliary Organoids in Cholestasis Research and Regenerative Medicine Seminars In Liver Disease 2021, 41: 206-212. PMID: 33957696, DOI: 10.1055/s-0041-1728663.
• Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case ReportGuercio BJ, Iyer G, Kidwai WZ, Lacouture ME, Ghafoor S, Rossi AM, Assis DN, Chen YB, Busam KJ, Janjigian YY, Jhaveri K, Feldman DR, Capozzi A, Figueroa V, Bajorin DF, Rosenberg JE, Hollmann TJ, Funt SA. Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report Case Reports In Oncology 2021, 14: 430-438. PMID: 33790764, PMCID: PMC7983595, DOI: 10.1159/000514345.
• Oral Vancomycin or Ursodeoxycholic Acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled TrialsAssis DN, Levy C. Oral Vancomycin or Ursodeoxycholic Acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials Hepatology 2021, 73: 887-889. PMID: 33403699, DOI: 10.1002/hep.31702.
• Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta‐Analyses Supporting American Association for the Study of Liver Diseases GuidelinesVierling JM, Kerkar N, Czaja AJ, Mack CL, Adams D, Assis D, Manns MP, Mayo MJ, Nayfeh T, Majzoub AMM, Alzuabi MA, Ding J, Haffar S, Murad MH, Alsawas M. Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta‐Analyses Supporting American Association for the Study of Liver Diseases Guidelines Hepatology 2020, 72: 753-769. PMID: 32500593, DOI: 10.1002/hep.31407.
• A Systematic Review of Patient‐Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing CholangitisKim HP, Lieber SR, Rogers ME, Moon AM, Loiselle M, Walker J, Assis DN, Safer R, Gomel R, Evon DM. A Systematic Review of Patient‐Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Hepatology Communications 2020, 4: 1502-1515. PMID: 33024919, PMCID: PMC7527768, DOI: 10.1002/hep4.1567.
• AS055 Co-culture of bile-derived organoids from primary sclerosing cholangitis patients with CD4+ T cells replicates pathogenic, CCL20 dependent biliary-immune interactionsSoroka C, Roberts S, Hohenester S, Boyer J, Assis D. AS055 Co-culture of bile-derived organoids from primary sclerosing cholangitis patients with CD4+ T cells replicates pathogenic, CCL20 dependent biliary-immune interactions Journal Of Hepatology 2020, 73: s41. DOI: 10.1016/s0168-8278(20)30634-6.
• Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to UrsodiolGhonem NS, Auclair AM, Hemme CL, Gallucci GM, Rodriguez R, Boyer JL, Assis DN. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol Clinical Pharmacology & Therapeutics 2020, 108: 1213-1223. PMID: 32480421, PMCID: PMC7886378, DOI: 10.1002/cpt.1930.
• Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver DiseasesMack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases Hepatology 2020, 72: 671-722. PMID: 31863477, DOI: 10.1002/hep.31065.
• Su1652 COMPREHENSIVE REVIEW OF PATIENT-REPORTED OUTCOME CONCEPTS AND INSTRUMENTS IN THE PBC AND PSC SCIENTIFIC LITERATUREKim H, Lieber S, Rogers M, Moon A, Loiselle M, Walker J, Assis D, Evon D. Su1652 COMPREHENSIVE REVIEW OF PATIENT-REPORTED OUTCOME CONCEPTS AND INSTRUMENTS IN THE PBC AND PSC SCIENTIFIC LITERATURE Gastroenterology 2020, 158: s-1375. DOI: 10.1016/s0016-5085(20)34105-6.
• Immunopathogenesis of Autoimmune HepatitisAssis DN. Immunopathogenesis of Autoimmune Hepatitis Clinical Liver Disease 2020, 15: 129-132. PMID: 32257125, PMCID: PMC7128031, DOI: 10.1002/cld.873.
• Machine Learning in a Complex Disease: PREsTo Improves the Prognostication of Primary Sclerosing CholangitisShung DL, Assis DN. Machine Learning in a Complex Disease: PREsTo Improves the Prognostication of Primary Sclerosing Cholangitis Hepatology 2020, 71: 8-10. PMID: 31850533, DOI: 10.1002/hep.31069.
• The Contribution of B Cells in Autoimmune Liver DiseasesTaylor SA, Assis DN, Mack CL. The Contribution of B Cells in Autoimmune Liver Diseases Seminars In Liver Disease 2019, 39: 422-431. PMID: 31226726, PMCID: PMC6800599, DOI: 10.1055/s-0039-1688751.
• Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel DiseasesLynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, van der Woude CJ, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK, Group I, Levy C. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases Clinical Gastroenterology And Hepatology 2019, 18: 179-187.e6. PMID: 31100458, PMCID: PMC6941216, DOI: 10.1016/j.cgh.2019.05.013.
• Patient-Derived Organoids from Human Bile: An In Vitro Method to Study CholangiopathiesSoroka CJ, Assis DN, Boyer JL. Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies 2019, 1981: 363-372. PMID: 31016667, DOI: 10.1007/978-1-4939-9420-5_24.
• Clinical utility of genomic analysis in adults with idiopathic liver diseaseHakim A, Zhang X, DeLisle A, Oral EA, Dykas D, Drzewiecki K, Assis DN, Silveira M, Batisti J, Jain D, Bale A, Mistry PK, Vilarinho S. Clinical utility of genomic analysis in adults with idiopathic liver disease Journal Of Hepatology 2019, 70: 1214-1221. PMID: 31000363, PMCID: PMC6526061, DOI: 10.1016/j.jhep.2019.01.036.
• Bile‐Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune ProfileSoroka CJ, Assis DN, Alrabadi LS, Roberts S, Cusack L, Jaffe AB, Boyer JL. Bile‐Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile Hepatology 2019, 70: 871-882. PMID: 30561836, DOI: 10.1002/hep.30470.
• The Immunopathogenesis of Autoimmune HepatitisClinical Liver Disease (in press)
• Histologic features of autoimmune hepatitis: a critical appraisalGurung A, Assis DN, McCarty TR, Mitchell KA, Boyer JL, Jain D. Histologic features of autoimmune hepatitis: a critical appraisal Human Pathology 2018, 82: 51-60. PMID: 30041025, DOI: 10.1016/j.humpath.2018.07.014.
• Chronic Complications of Cholestasis Evaluation and ManagementAssis DN. Chronic Complications of Cholestasis Evaluation and Management Clinics In Liver Disease 2018, 22: 533-544. PMID: 30259851, DOI: 10.1016/j.cld.2018.03.014.
• Chapter 43: Primary and Secondary Sclerosing CholangitisBowlus CL, Assis DN, Goldberg DS. Zakim and Boyer’s Hepatology: A Textbook of Liver Disease. Elsevier (7th Edition).
• 43 Primary and Secondary Sclerosing CholangitisBowlus C, Assis D, Goldberg D. 43 Primary and Secondary Sclerosing Cholangitis 2018, 626-647.e6. DOI: 10.1016/b978-0-323-37591-7.00043-4.
• Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American ConsortiumGoldberg DS, Levy C, Yimam K, Gordon SC, Forman L, Verna E, Yu L, Rahimi R, Schwarz K, Eksteen B, Pratt D, Boyer JL, Assis D, Bowlus C. Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium Clinical Gastroenterology And Hepatology 2017, 16: 591-593. PMID: 29102704, PMCID: PMC5860952, DOI: 10.1016/j.cgh.2017.10.028.
• Gallbladder and bile duct disease in Cystic FibrosisAssis DN, Debray D. Gallbladder and bile duct disease in Cystic Fibrosis Journal Of Cystic Fibrosis 2017, 16: s62-s69. PMID: 28986023, DOI: 10.1016/j.jcf.2017.07.006.
• Mo1444 Prevalence of Primary Sclerosing Cholangitis in Black Patients: Results of a Multi-Center North American ConsortiumGoldberg D, Yimam K, Eksteen B, Levy C, Pratt D, Schwarz K, Forman L, Yu L, Rahimi R, Assis D, Bowlus C. Mo1444 Prevalence of Primary Sclerosing Cholangitis in Black Patients: Results of a Multi-Center North American Consortium Gastroenterology 2017, 152: s1185. DOI: 10.1016/s0016-5085(17)33954-9.
• Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing CholangitisAssis DN, Abdelghany O, Cai SY, Gossard AA, Eaton JE, Keach JC, Deng Y, Setchell KD, Ciarleglio M, Lindor KD, Boyer JL. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis Journal Of Clinical Gastroenterology 2017, 51: e11-e16. PMID: 27428727, PMCID: PMC5218875, DOI: 10.1097/mcg.0000000000000591.
• FRI-393 Macrophage migration inhibitory factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver diseaseRoberts S, Leng L, Soroka C, Boyer J, Bucala R, Assis D. FRI-393 Macrophage migration inhibitory factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver disease Journal Of Hepatology 2017, 66: s363-s364. DOI: 10.1016/s0168-8278(17)31067-x.
• A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese PatientsAssis DN, Takahashi H, Leng L, Zeniya M, Boyer JL, Bucala R. A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients Digestive Diseases And Sciences 2016, 61: 3506-3512. PMID: 27696094, PMCID: PMC5106299, DOI: 10.1007/s10620-016-4322-z.
• The clinical significance of the MIF homolog d-dopachrome tautomerase (MIF-2) and its circulating receptor (sCD74) in burnKim BS, Stoppe C, Grieb G, Leng L, Sauler M, Assis D, Simons D, Boecker AH, Schulte W, Piecychna M, Hager S, Bernhagen J, Pallua N, Bucala R. The clinical significance of the MIF homolog d-dopachrome tautomerase (MIF-2) and its circulating receptor (sCD74) in burn Burns 2016, 42: 1265-1276. PMID: 27209369, PMCID: PMC5010466, DOI: 10.1016/j.burns.2016.02.005.
• The interpretation of hepatic venous pressure gradient tracings – excellent interobserver agreement unrelated to experienceTandon P, Ripoll C, Assis D, Wongcharatrawee S, Groszmann RJ, Garcia-Tsao G. The interpretation of hepatic venous pressure gradient tracings – excellent interobserver agreement unrelated to experience Liver International 2016, 36: 1160-1166. PMID: 26763558, DOI: 10.1111/liv.13065.
• Gastrointestinal Disorders in Cystic FibrosisAssis DN, Freedman SD. Gastrointestinal Disorders in Cystic Fibrosis Clinics In Chest Medicine 2015, 37: 109-118. PMID: 26857772, DOI: 10.1016/j.ccm.2015.11.004.
• Editorial: environmental risk factors for PSC with and without IBD – the story unfoldsAssis DN, Levy C. Editorial: environmental risk factors for PSC with and without IBD – the story unfolds Alimentary Pharmacology & Therapeutics 2015, 41: 1214-1216. PMID: 25939466, DOI: 10.1111/apt.13186.
• Fibrates and cholestasisGhonem NS, Assis DN, Boyer JL. Fibrates and cholestasis Hepatology 2015, 62: 635-643. PMID: 25678132, PMCID: PMC4515188, DOI: 10.1002/hep.27744.
• The role of macrophage migration inhibitory factor in autoimmune liver diseaseAssis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, Mizue Y, Nikolic‐Paterson D, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, Bucala R. The role of macrophage migration inhibitory factor in autoimmune liver disease Hepatology 2013, 59: 580-591. PMID: 23913513, PMCID: PMC3877200, DOI: 10.1002/hep.26664.
• Now you see it, now you don'tPlotkin E, Assis D, Boyer J. Now you see it, now you don't Hepatology 2013, 58: 446-447. DOI: 10.1002/hep.26439.
• Now you see it, now you don’t.Plotkin E, Assis DN, Boyer JL. Hepatology. 2013;58:446-447 (Case Report)
• New Pharmacotherapy for Hepatitis CAssis DN, Lim JK. New Pharmacotherapy for Hepatitis C Clinical Pharmacology & Therapeutics 2012, 92: 294-305. PMID: 22850602, DOI: 10.1038/clpt.2012.103.
• Successful Treatment of a Bleeding Umbilical Varix by Percutaneous Umbilical Vein Embolization With SclerotherapyAssis DN, Pollak J, Schilsky ML, Emre S. Successful Treatment of a Bleeding Umbilical Varix by Percutaneous Umbilical Vein Embolization With Sclerotherapy Journal Of Clinical Gastroenterology 2012, 46: 115-118. PMID: 21897280, DOI: 10.1097/mcg.0b013e31822b7f9a.
• Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver TransplantationCimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S. Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation Transplantation Proceedings 2011, 43: 905-908. PMID: 21486625, DOI: 10.1016/j.transproceed.2011.02.034.
• Testing and management of thrombocytopenia and coagulopathy in the pre- and postliver transplant patient.Assis DN, Schilsky ML. Testing and management of thrombocytopenia and coagulopathy in the pre- and postliver transplant patient. Minerva Gastroenterology 2010, 56: 331-43. PMID: 21037549.
• Human drug hepatotoxicity: a contemporary clinical perspective.Assis DN, Navarro VJ. Human drug hepatotoxicity: a contemporary clinical perspective. Expert Opinion On Drug Metabolism & Toxicology 2009, 5: 463-73. PMID: 19416083, DOI: 10.1517/17425250902927386.
• Dilated cisternae chyli: a sign of uncompensated cirrhosis at MR imaging.Verma SK, Mitchell DG, Bergin D, Lakhman Y, Austin A, Verma M, Assis D, Herrine SK, Parker L. Dilated cisternae chyli: a sign of uncompensated cirrhosis at MR imaging. Abdominal Imaging 2009, 34: 211-6. PMID: 18219518, DOI: 10.1007/s00261-008-9369-7.
• Post-sphincterotomy transampullary balloon dilation is a safe and effective technique.Kowalski T, Nathwani RA, Assis D, Salese L, Banwait K, Loren D. Post-sphincterotomy transampullary balloon dilation is a safe and effective technique. Digestive Diseases And Sciences 2009, 54: 670-4. PMID: 18594970, DOI: 10.1007/s10620-008-0376-x.
• Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations.Rossi S, Assis DN, Awsare M, Brunner M, Skole K, Rai J, Andrel J, Herrine SK, Reddy RK, Navarro VJ. Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations. Drug Safety 2008, 31: 261-70. PMID: 18302450, DOI: 10.2165/00002018-200831030-00007.
• Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones.Mylin LM, Schell TD, Epler M, Kusuma C, Assis D, Matsko C, Smith A, Allebach A, Tevethia SS. Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. Virology 2007, 364: 155-68. PMID: 17368499, PMCID: PMC3866617, DOI: 10.1016/j.virol.2007.02.007.